ReviewEuropean child & adolescent psychiatry2012
Efficacy and safety of aripiprazole in child and adolescent patients.
Review in European child & adolescent psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.The Indian journal of medical research · 2015Pooled it
- Physical exercise therapy for autism spectrum disorder: protocol for a scoping review of systematic reviews.Systematic reviews · 2026Article
- Rescue of cognitive and negative-like symptoms by chronic aripiprazole treatment in a 3-hit mouse model of neurodevelopmental disorder.Frontiers in pharmacology · 2026Article
- Nanogels Based on N,N-Dimethylacrylamide and β-Cyclodextrin Triacrylate for Enhanced Solubility and Therapeutic Efficacy of Aripiprazole.Gels (Basel, Switzerland) · 2024Article
- Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns.The mental health clinician · 2024Article
- Spectrofluorometric quantitative analysis of aripiprazole based on quenching of natural derived carbon quantum dots in spiked human plasma.Scientific reports · 2023Article
- Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model.International journal of molecular sciences · 2021Article
- The Impact of the Preparation Method on the Properties of Orodispersible Films with Aripiprazole: Electrospinning vs. Casting and 3D Printing Methods.Pharmaceutics · 2021Article
- Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019Article
- An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options.Neuroscience bulletin · 2017Review
- Prefrontal Dopaminergic Mechanisms of Extinction in Adolescence Compared to Adulthood in Rats.Frontiers in behavioral neuroscience · 2017Article
- Irritability and Severity of Anxious Symptomatology Among Youth With Anxiety Disorders.Journal of the American Academy of Child and Adolescent Psychiatry · 2016Article
- Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial.Annals of general psychiatry · 2016Article
- The cost of inpatient care of schizophrenia in the Polish and Ukrainian academic centers--Poznan and Lviv.Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry · 2015Article
- Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.Journal of psychopharmacology (Oxford, England) · 2014Article
- The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome.BMJ case reports · 2014Article
- Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents.Adolescent health, medicine and therapeutics · 2014Review
- Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.Clinical medicine insights. Pediatrics · 2014Review
- Psychopharmacological treatment in children: always keeping an eye on adherence and ethics.European child & adolescent psychiatry · 2013Article
- Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aripiprazole (APZ) has a unique pharmacological profile, as a partial agonist at the dopamine D2 and serotonin 5HT1A receptors and an antagonist at the serotonin 5HT2A receptor; this drug has few side effects (such as extrapyramidal syndrome, hyperprolactinemia, weight gain, metabolic disorders, and sedation) which are typical problems with other antipsychotic drugs. Due to its high tolerability, it is possible to safely administer it to children and adolescents. Efficacy and tolerability of APZ in children and adolescents have been well demonstrated in many clinical studies, which supported approvals granted by the US Food and Drug Administration (FDA) for schizophrenia, bipolar diseases, and irritability associated with autistic disorder in children and adolescents. APZ is expected to exert sedative, anti-depressive, and anti-anxiety effects, and stabilize emotion. APZ is an antipsychotic drug which could be useful for a wider spectrum of psychiatric disorders in children and adolescents. There is little risk of deterioration (such as disinhibition and acting out) and rapid stabilization is easy to achieve in children and adolescents without definitive diagnoses or with a combination of more than one spectrum of disorders. The effectiveness of APZ in children and adolescents is reviewed and discussed, given its pharmacological profile and the outcomes of various clinical studies. However, randomized or blind studies are still limited, and the majority of reports referenced here are open-label studies and case reports. Conclusions drawn from such studies must be evaluated with caution, and a further accumulation of controlled studies is thus needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.